Carnitine, Total, Serum/Plasma
Carnitine or β-hydroxy-γ-trimethylammonium butyrate is synthesized in the liver and kidney from lysine and methionine. It can also be obtained from the diet, primarily from meat products. Carnitine plays a very important role in the transportation of long-chain fatty acyl-CoA molecules from the cytosol into mitochondria where it is oxidized to generate energy. Therefore, carnitine is required for energy production from fat. Deficiency of carnitine is associated with impaired energy production and causes symptoms mostly in the fasting state. Evaluation of carnitine in serum and urine provide valuable information in regard to primary and secondary disorders of the carnitine cycle.
Primary carnitine deficiency, also known as carnitine update defect (CUD) is an autosomal recessive disorder, characterized by a defect in the carnitine/organic cation transporter novel 2 (OCTN2). In this disorder, fatty acyl CoA cannot be transported into mitochondria, resulting in impaired fatty acid oxidation. Due to the lack of carnitine transporter in the plasma membrane, intracellular carnitine content is significantly decreased while urinary excretion accelerates. Therefore, significant amounts (50 – 90%) of carnitine is lost in the urine. The incidence of CUD is approximately 1:40,000 newborns in the US population. Patients can present with hepatic encephalopathy or cardiomyopathy. Laboratory studies may show fasting hypoglycemia with minimal or no ketonuria, hyperammonemia and hepatic dysfunction. Secondary deficiency of carnitine may occur as a result of organic acidemias and disorders in fatty acid oxidation in which carnitine is trapped as fatty acyl CoA in cells resulting in its toxic accumulation and excretion into urine and bile as acylcarnitine. Rarely carnitine deficiency may occur in severe liver disease, malnutrition, total parenteral nutrition, chronic renal disease and patients on hemodialysis.
- Aid in the diagnosis of primary and secondary carnitine deficiency
- Useful in assessment of disorder in carnitine cycle and fatty acid oxidation
- Useful in differential diagnosis of organic acidemias and fatty acid oxidation disorders
- Useful in monitoring carnitine status
Increased in:
- Myoglobinuria
- Carnitine supplementation
- After meat consumption
Decreased in:
- Primary carnitine deficiency (carnitine update defect)
- Carnitine palmitoyl transferase 1 deficiency
- Carnitine palmitoyl transferase 2 deficiency
- Carnitine-acylcarnitine translocase deficiency
- Severe liver disease,
- Malnutrition,
- Total parenteral nutrition,
- Chronic kidney disease
- Hemodialysis
| Serum Age Group | Reference Range |
| 1 day | 23 – 68 μmol/L |
| 2–7 days | 17 – 41 μmol/L |
| 8–31 days | 19 – 59 μmol/L |
| 1 month – 1 year | 38 – 68 μmol/L |
| 1 year – 6 years | 35 – 84 μmol/L |
| 7 – 10 years | 28 – 83 μmol/L |
| 11 – 18 years | 34 – 77 μmol/L |
| >18 years | 34 – 78 μmol/L |
Serum (SST), plasma (EDTA)
Stability
- Ambient: 3 hours
- Refrigerated: 12 hours
- Frozen: 1 month (avoid repeated freeze/thaw cycle)
- Eur J Pediatr. 1988;147(4):356-60. [PMID: 3396591]
- Clin Chem. 2000;46(5):727-9. [PMID: 10794762]
- Orphanet J Rare Dis. 2012;7:68. [PMID: 22989098]
- Am J Med Genet C Semin Med Genet. 2006;142C(2):77-85. [PMID: 16602102]
- Molecules. 2019 Sep 6;24(18). pii: E3251. [PMID: 31500110]
- Pasquali M and Longo N. Newborn Screening and Inborn Errors of Metabolism. In Textbook of Clinical Chemistry and
- Molecular Diagnostics. 6th ed. 2018. Page 1698 – 1730